| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Advances in Brief |
Expression Contributes to the Maintenance of Elevated Cyclooxygenase-2 in Non-Small Cell Lung Cancer Cells1
University of California at Los Angeles Lung Cancer Research Program of the Jonsson Comprehensive Cancer Center and the Division of Pulmonary and Critical Care Medicine, Department of Medicine, David Geffen School of Medicine at University of California at Los Angeles, and the Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California 90095
Non-small cell lung cancer (NSCLC) cells are known to constitutively overexpress cyclooxygenase (COX)-2. Tumor COX-2-dependent production of PGE2 triggers the synthesis of lymphocyte and macrophage interleukin (IL)-10 that, in turn, is known to potently suppress COX-2 in normal cells. Thus, we investigated the capacity of IL-10 to down-regulate COX-2 expression in NSCLC cells. Western blotting and ELISA analyses revealed that IL-10 did not affect COX-2 expression and subsequent PGE2 production in NSCLC cells. Although normal human bronchial epithelial cells expressed both intracellular and membrane IL-10R
, NSCLC cells only expressed intracellular but not cell surface membrane IL-10R. Unresponsiveness of COX-2 to IL-10 is due to the deficiency of IL-10R on the surface of NSCLC cells. Our findings highlight a novel mechanism contributing to maintenance of elevated COX-2 and PGE2 in the lung tumor environment.
This article has been cited by other articles:
|
|
 |
|
  T. Walser, X. Cui, J. Yanagawa, J. M. Lee, E. Heinrich, G. Lee, S. Sharma, and S. M. Dubinett Smoking and Lung Cancer: The Role of Inflammation Proceedings of the ATS, December 1, 2008; 5(8): 811 - 815. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Dubinett,, J. T. Mao, and S. Hazra Focusing Downstream in Lung Cancer Prevention: 15-Hydroxyprostaglandin Dehydrogenase Cancer Prevention Research, September 1, 2008; 1(4): 223 - 225. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Liu, S.-C. Yang, S. Sharma, J. Luo, X. Cui, K. A. Peebles, M. Huang, M. Sato, R. D. Ramirez, J. W. Shay, et al. EGFR Signaling Is Required for TGF-beta1 Mediated COX-2 Induction in Human Bronchial Epithelial Cells Am. J. Respir. Cell Mol. Biol., November 1, 2007; 37(5): 578 - 588. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Hazra, R. K. Batra, H. H. Tai, S. Sharma, X. Cui, and S. M. Dubinett Pioglitazone and Rosiglitazone Decrease Prostaglandin E2 in Non-Small-Cell Lung Cancer Cells by Up-Regulating 15-Hydroxyprostaglandin Dehydrogenase Mol. Pharmacol., June 1, 2007; 71(6): 1715 - 1720. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Mocellin, F. M. Marincola, and H. A. Young Interleukin-10 and the immune response against cancer: a counterpoint J. Leukoc. Biol., November 1, 2005; 78(5): 1043 - 1051. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Akasaki, G. Liu, N. H. C. Chung, M. Ehtesham, K. L. Black, and J. S. Yu Induction of a CD4+ T Regulatory Type 1 Response by Cyclooxygenase-2-Overexpressing Glioma J. Immunol., October 1, 2004; 173(7): 4352 - 4359. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Brown and R. N. DuBois Cyclooxygenase-2 in Lung Carcinogenesis and Chemoprevention: Roger S. Mitchell Lecture Chest, May 1, 2004; 125(5_suppl): 134S - 140S. [Full Text] [PDF]
|
|
|
|
 |
|
 P. DeLong, T. Tanaka, R. Kruklitis, A. C. Henry, V. Kapoor, L. R. Kaiser, D. H. Sterman, and S. M. Albelda Use of Cyclooxygenase-2 Inhibition to Enhance the Efficacy of Immunotherapy Cancer Res., November 15, 2003; 63(22): 7845 - 7852. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
